Bibliographic record
Abstract
Introduction In the early 1980s the United Kingdom took a pioneering role in the area of new reproductive technologies (NRTs). Significant strides were made not only in terms of scientific and clinical development, but also in relation to relevant legal and ethical issues. In the latter category, attempts were made to address the debate concerning the moral status of human embryos by advocating a for research: the Warnock Report, published in 1985, stipulated that research with human embryos only be allowed up to 14 days after fertilization, the point at which the three germ layers typically become distinct. (1) To many, the proposed moral dividing line was purely arbitrary, yet somehow a quasi-break in the ontogeny of a human being came to be used as a legitimate demarcation point. (2) In 1990, the U.K. entrenched the 14-day limit in the Human Fertilisation and Embryology Act, (3) and since then most other industrialized nations that permit embryo research have followed suit. Draft legislation in Canada, (4) an opinion report issued by France's Comite Consultatif National d'Ethique (CCNE), (5) the Netherlands' Embryos Bill, (6) and Australia's National Health and Medical Research Council (NHMRC) (7) all expressly endorse the U.K. position. The United States' National Institutes of Health (NIH) has identified the formation of the mesoderm as the appropriate limit for embryo research, and notably this coincides with the 14-day limits. (8) At present it is interesting to speculate about whether the U.K. will set the standard for embryonic stem cell research. In January of this year, after lengthy debates, the U.K. Parliament passed the Human Fertilisation and Embryology (Research Purposes) Regulations 2001, (9) permitting embryonic stem cell research using either in vitro fertilization (IVF) or somatic cell nuclear transfer (SCNT) technology, and thereby condoning therapeutic cloning. For the time being, this position is unique to the U.K. As policymakers around the world scramble to take a stance on this hotly debated issue, the question is: will the U.K. lead the way once again? Or, in the alternative, is the U.K. framework regulating embryonic stem cell research flawed, leaving other nation-states to formulate a different set of standards? A. Reacting to the Science: A Comparative Analysis In this article, the likelihood that the U.K. position will become the international position is assessed by way of comparison, examining guidelines and reports issued by governments and quasi-governmental bodies in Canada, (10) the United States, (11) the United Nations, (12) Europe, (13) France, (14) the Netherlands, (15) Germany, (16) and Australia. (17) The comparison, illustrative rather than comprehensive, focuses on key aspects of the U.K. scheme, namely: (1) the nature of the research; (2) the origin of the embryonic stem cells; (3) issues surrounding consent; (4) safeguards against commercialization; (5) directed donation; (6) animal/human hybrids and chimeras; (7) oversight mechanisms and the scope of the regulatory framework. It will examine these aspects in relation to policies developed by other jurisdictions. Points of agreement as well as inconsistencies will be highlighted, the goal being to critically evaluate the U.K.'s initiative as a likely or potential international consensus position. (1) Nature of the Research Stem cells can be derived from a variety of sources, including adult tissues, umbilical cords, aborted fetuses, and embryos. The present discussion focuses on stem cells of embryonic origin (ES cells). ES cells are derived from the isolated inner cell mass of early embryos, cultured to the blastocyst stage. (18) The Human Fertilisation & Embryology Authority (HFEA), created under s. 5(1) of the HFE Act, is the licensing body for research involving embryos (according to s. 9(1) of the HFE Act). Assuming a particular research project satisfies one of the five purposes relating to reproduction described in Schedule 2, s. …
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.028 | 0.054 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.003 |
| Science and technology studies | 0.003 | 0.012 |
| Scholarly communication | 0.014 | 0.014 |
| Open science | 0.003 | 0.007 |
| Research integrity | 0.011 | 0.010 |
| Insufficient payload (model declined to judge) | 0.024 | 0.007 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".